| ROC Area (95% CI) | Cut-Off Point | Sensitivity (%) | Specificity (%) |
---|---|---|---|---|
Discovery cohort | ||||
Donor Terminal Creatinine(mg/dL) | 0.753(0.622–0.883) | 1.3178 | 60.9% | 87.5% |
Donor history of diabetes mellitus | 0.655(0.510–0.799) | 0.5 | 43.5% | 87.5% |
 CIT(h) | 0.706(0.573–0.839) | 11.25 | 43.5% | 91.7% |
Donor IL-2(pg/mL) | 0.714(0.585–0.843) | 66.415 | 95.7% | 45.8% |
Prediction_system | 0.894(0.798–0.955) | -0.896 | 86.96% | 85.42% |
 KDRI | 0.764(0.649–0.857) | 1.13 | 82.61% | 62.50% |
 DGFS | 0.720(0.601–0.820) | 0.2767 | 69.57% | 66.67% |
Validation cohort | ||||
 Donor Terminal Creatinine(mg/dL) | 0.817(0.640–0.931) | 0.676 | 91.7% | 65% |
Donor history of diabetes mellitus | 0.625(0.437–0.789) | 0 | 25% | 100% |
 CIT(h) | 0.769(0.586–0.899) | 8 | 83.33% | 65% |
Donor IL-2(pg/mL) | 0.819(0.643–0.932) | 87.11 | 100% | 55% |
Prediction_system | 0.879(0.715–0.967) | -0.984 | 0.8333 | 0.800 |
 KDRI | 0.829(0.655–0.938) | 0.80 | 100% | 60% |
 DGFS | 0.667(0.479–0.823) | 0.327 | 66.7% | 80% |